Table 2.
COVID-19 Incidence by Treatment Group
| At Risk | |||||
|---|---|---|---|---|---|
| Outcome: Treatment Group | No. | Total PY | No. With Event | Incidence Rate per 100 PYa (95% CI) | Incidence Rate Ratiob (95% CI) |
| COVID-19 | |||||
| Pitavastatin | 3451 | 9890 | 869 | 8.79 (8.22–9.39) | 1.05 (.96–1.16) |
| Placebo | 3454 | 9967 | 832 | 8.35 (7.80–8.93) | … |
| Serious COVID-19 | |||||
| Pitavastatin | 3451 | 11 099 | 50 | 0.45 (.34–.59) | 0.75 (.52–1.08) |
| Placebo | 3454 | 11 080 | 67 | 0.60 (.48–.77) | … |
| Serious COVID-19 on treatmentc | |||||
| Pitavastatin | 3123 | 10 138 | 42 | 0.41 (.31–.56) | 0.73 (.49–1.08) |
| Placebo | 3058 | 9936 | 57 | 0.57 (.44–.74) | … |
No. refers to number of participants.
Abbreviation: CI, confidence interval; PY, person-years.
aEvent incidence was estimated as the number of participants with events divided by the total person-years of follow-up at risk, with follow-up time calculated from 1 January 2020 to the first event or last contact, whichever was earlier.
bIncidence rate ratios (reference: placebo) from Poisson models, adjusted for Global Burden of Disease region.
cSerious COVID-19 among those on treatment as of 1 January 2020.